B-cell acute lymphoblastic leukemia pediatric · 12 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Blinatumomab monotherapy Variant #05 | — | R 4 812 257 | 56d | — | ~7.7 mo | ~1 | ~R 4 812 257 PFS proxy · indirect | 2 |
Daunorubicin and Prednisone Variant #01 Partial | — | R 16 547 | 42d | — | — | ~1 | ~R 16 547 indirect | — |
Mitoxantrone, Asparaginase Erwinia chrysanthemi, Vincristine, Dexamethasone Variant #01 Partial | — | R 9 516 | 28d | — | — | ~1 | ~R 9 516 indirect | — |
Mitoxantrone, Pegaspargase, Vincristine, Dexamethasone Variant #01 Partial | — | R 9 516 | 28d | — | — | ~1 | ~R 9 516 indirect | — |
DOLP Variant #16 Partial | — | R 9 311 | 42d | — | — | ~1 | ~R 9 311 indirect | — |
CCE Variant #01 Partial | — | R 3 579 | 5d | — | — | ~1 | ~R 3 579 indirect | — |
Doxorubicin, Pegaspargase, Vincristine, Prednisone Variant #01 Partial | — | R 2 008 | 35d | — | — | ~1 | ~R 2 008 indirect | — |
Cyclophosphamide monotherapy Variant #01 | — | R 1 680 | 28d | — | ~15.8 mo | ~1 | ~R 1 680 PFS proxy · indirect | 1 |
L-Asparaginase, Vincristine, Prednisone Variant #01 Partial | — | R 549 | 28d | — | — | ~1 | ~R 549 indirect | — |
Clofarabine monotherapy Variant #01 Partial | — | — | 42d | — | — | ~12 | — | 1 |
Inotuzumab ozogamicin monotherapy Variant #01 Partial | — | — | 28d | — | ~7.7 mo | ~5 | — | 1 |
Tisagenlecleucel monotherapy Variant #01 Partial | — | — | — | — | — | ~1 | — | — |
12 of 12 regimens shown